Medica S p A : 24.04.2024 14.20 - Medica SpA – Ordinary and extrordinary shareholders meeting of 24 april 2024

MEDICA S.p.A.	Tel. [phone]
Via Degli Artigiani, 7	Fax [phone]
41036 MEDOLLA	[e-mail]
MODENA - ITALY	www.medica-spa.com

Press release

MEDICA S.P.A.

APPROVED THE FINANCIAL STATEMENT AS OF 31 DECEMBER 2023 AND

THE DESTINATION OF THE NET INCOME; PRESENTED THE

CONSOLIDATED FINANCIAL STATEMENT AS OF 31 DECEMBER 2023;

APPOINTED THE BOARD OF DIRECTORS; AMENDED THE ART. 35 OF THE

STATUTE

Medolla (MO), 24 april 2024 - The Board of Directors of Medica S.p.A., an integrated Italian biomedical and MedTech group with a strong international footprint, announces that the ordinary shareholders' meeting, held today under the chairmanship of Luciano Fecondini, approved the financial statements as at 31 December 2023, closed with a net profit of Euro 2,590,977, together with the proposal of the Board of Directors to allocate the profit for the year to the legal reserve for Euro 129,549, equal to 5% of the profit, and to the statutory reserve for Euro 2,461,428.

The Assembly also took note of the results of the consolidated financial statements as at 31 December 2023 and appointed the Board of Directors for the three-year period up to the Assembly for the approval of the financial statements as at 31 December 2026, approving the only list with the proposals of resolutions received from the shareholder Pelmo87 Srl.

The Euronext Growth Advisor has successfully verified the existence of the independence requirements of the director Andrea Moschetti.

The extraordinary meeting held today under the chairmanship of Luciano Fecondini approved the amendment of art. 35 of the Articles of Association to implement the provisions of the recent amendment to the Issuers' Regulation, which specifically requires that the assessment of the existence of the independence requirements for the directors must be carried out, in the phase following admission to trading, by the Board of Directors and no longer by the Euronext Growth Advisor.

The Board of Directors in compliance with the changes made by notice no. 43747 published on 17 November 2023 by Borsa Italiana S.p.A. to the art. 6-bis of the Issuers' Regulations Euronext Growth Milan approved in the session of 24 April 2024, which took place after the aforementioned extraordinary meeting, the Regulation which defines the quantitative and qualitative criteria of significance of relationships potentially relevant for the purposes of assessing the independence of directors, which will therefore be adopted after the aforementioned statutory amendment.

The Regulation is available on the website www.medica-spa.com, Corporate Governance section, corporate documents.

UNI CEI EN ISO 9001:2015 UNI CEI EN ISO 13485:2016

Capitale sociale € 4.223.250,00 i.v. - Registro Ditte/REA n° 229672 - Registro Imprese di Modena n° 01604300366 Iscrizione Registro Nazionale Produttori A.E.E. n. IT08020000003645

Partita IVA e Codice Fiscale 01604300366 - Identification Number IT 01604300366

Pagina 1 di 2

MEDICA S.p.A.	Tel. [phone]
Via Degli Artigiani, 7	Fax [phone]
41036 MEDOLLA	[e-mail]
MODENA - ITALY	www.medica-spa.com

The company announces that a copy of the 2023 financial statements of Medica Spa and the 2023 consolidated financial statements of the Medica Group can be consulted at the registered office, as well as on the Medica Spa website www.medica-spa.com, in the 'Investors/Balance sheet' and on the Borsa Italiana website. It is also specified that this press release is published on the Medica Spa website www.medica-spa.com, in the 'Investors / Press Releases' section.

The minutes of today's meeting will be made available within the terms of current legislation and will be available for consultation at the registered office, as well as on the Medica Spa website www.medica-spa.com, in the 'Investors/Shareholders' Meeting' section and on Borsa Italiana website.

***

Medica Profile

Medica Group is operating since 1985 in the biomedical district of Mirandola (Italy). Development of innovative products for blood purification has always been company's core business. Thanks to the activity of two extremely dynamic R&D groups (medical equipment, membranes and disposable), the Group competes successfully in several markets, namely:

• Medical (dialysis, CRRT, ECCO2, Apheresis, DFPP, CHF, HIPEC, pre-transplant organ perfusion, bioregenerative medicine, gastroenterology, urodynamics, oxygen humidification).

• Microbiological purification of water

• Industrial automation for the biomedical sector.

R&D focus has been integrated over the years with a highly automated production systems in several facilities, and with different commercial entities, both in Italy and abroad.

The key success factors of the Group are:

• extrusion of hollow fiber membranes for hemofiltration, plasmapheresis, cascade filtration, oxygen humidification, ultrafiltration and microfiltration of water
• vertical integration, proved by the ability to manage not only the design and development of medical disposables and equipment, and the development of the automation technologies required for their production as well.
• International recognition with significant share of export, with sales in over 60 countries.

For information:

Investor Relations MedicaGiovanni Plasmati ([phone] [e-mail]

Euronext Growth Advisor

CFO SIM S.p.A.

([phone] [e-mail]

UNI CEI EN ISO 9001:2015	Capitale sociale € 4.223.250,00 i.v. - Registro Ditte/REA n° 229672 - Registro Imprese di Modena n° 01604300366
UNI CEI EN ISO 13485:2016	Iscrizione Registro Nazionale Produttori A.E.E. n. IT08020000003645
Partita IVA e Codice Fiscale 01604300366 - Identification Number IT 01604300366
	Pagina 2 di 2